Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

INSANE: 3 - The Real Truth

Moderna: 4 Key Reasons the CEO Just Bought $5M in Shares

Moderna stock has fallen to levels not seen in 5 years, but the CEO just spent $5 million buying stock in the open market underscoring his optimism for gains.

MarketBeat

Moderna: A Generational Opportunity for Investors in 2025

Moderna had a weak quarter but reaffirmed guidance, expecting three new product approvals in 2025 and as many as ten more within three years.

MarketBeat

Do Wall Street Analysts Like Moderna Stock?

Moderna has continued to underperform the broader market over the past year and analysts remain cautious about the stock’s prospects.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Here's What to Expect From Moderna's Next Earnings Report

Moderna is scheduled to release its fourth-quarter earnings next month, and analysts anticipate a significant triple-digit profit dip.

Barchart

After a Reset Year, Is Moderna Stock Poised for a Comeback?

Moderna had a rough 2024 and is starting 2025 with lowered forecasts, but is focused on getting 10 FDA approvals in the next three years. Is now time to buy?

MarketBeat

Moderna Stock Plummets 16% After £819.59M Guidance Cut Over Respiratory Vaccine Flop

Moderna is expediting its cost-cutting program and rolling back R&D amid a drop in vaccination rates and low revenues from a new vaccine.

International Business Times UK

Moderna Stock Is Volatile Amid Bird Flu Developments

Moderna stock has been volatile this week as the first death in the U.S. connected to bird flu was reported. Here's what you need to know.

Kiplinger

Read news from The Economist, FT, and more,
with one subscription

What Were the 4 Worst-Performing Stocks in the S&P 500 in 2024?

As 2025 starts to unfold, let's take a look back at the four worst-performing stocks in the S&P 500 from last year.

Barchart

Moderna Shares Spike on H5N1 News—What’s Next for Investors?

MRNA stock surged over 12% on growing bird flu concerns; that rally may not last, but analysts believe the company's pipeline makes the stock a Buy in 2025

MarketBeat

Stock Market Today: Stocks Are Mixed Ahead of the Fed

Two of the three main equity indexes closed higher on the first day of the final Fed Week of 2024.

Kiplinger

Is Moderna Stock Underperforming the Dow?

Moderna has significantly underperformed the Dow over the past year, and analysts are cautious about the stock’s prospects.

Barchart

2 Vaccine Stocks to Buy on the Dip

Given the cutting-edge pipeline for these two vaccine companies, double-digit slumps in these stocks present a compelling entry point for investors.

Barchart

Moderna Stock Outlook: Is Wall Street Bullish or Bearish?

Moderna has underperformed the broader market and its peers over the past year, and Wall Street analysts are cautious about the stock’s prospects.

Barchart

Stocks Extend Post-Election Gains Ahead of the FOMC Meeting

The S&P 500 Index ($SPX ) (SPY ) today is up +0.36%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.11%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.84%. Stocks today are moderately higher, with the S&P 500, the Dow Jones Industrials, and...

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Earnings Preview: What to Expect From Moderna's Report

Moderna is all set to release its fiscal third-quarter earnings next month, and analysts project its loss to rise in double digits.

Kiplinger

Moderna Stock Plunges as Vaccine Maker Slashes R&D Budget: What to Know

Moderna stock is plunging Thursday after the COVID-19 vaccine maker announced plans to drastically cut its R&D spending to focus on new product approvals.

Barchart

Is Moderna Stock Underperforming the Nasdaq?

While Moderna has underperformed the broader Nasdaq index in 2024, analysts are reasonably bullish about the stock's potential.

Barchart

Are Wall Street Analysts Predicting Moderna Stock Will Climb or Sink?

Moderna has underperformed many of its peers and the broader market YTD, but Wall Street analysts are optimistic about the stock’s prospects.

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Moderna's Quarterly Earnings Preview: What You Need to Know

Moderna is expected to release its fiscal second-quarter earnings next month, and analysts project a narrower loss.

Barchart

Is Moderna Stock Outperforming the S&P 500?

Moderna recently outperformed the S&P 500, and Wall Street analysts are moderately optimistic about the stock’s prospects.

Barchart

Is This Biotech Stock's OpenAI Partnership a Game-Changer?

With AI making waves in biotech, could this biotech’s OpenAI partnership be the catalyst for new highs?

Barchart

Is Wall Street Bullish or Bearish on Moderna Stock?

Moderna has outperformed many of its peers and the broader market YTD, but Wall Street analysts are cautiously optimistic about the stock's prospects.

StockNews.com

Biotech Investors: Should You Buy, Hold, or Sell Moderna (MRNA) and Arrowhead Pharmaceuticals (ARWR)?

Despite facing several challenges, the biotech sector thrives due to growing demand for effective treatments, consistent innovations, and a sustained demand for high-quality drugs and therapies. Let's assess whether one should Buy, Hold, or Sell biotech stocks Moderna (MRNA) and Arrowhead Pharmaceuticals (ARWR). Keep reading.

StockNews.com

Moderna (MRNA) Earnings Analysis: Buy or Watch for Gains?

Moderna’s (MRNA) mRNA platform is positioned to deliver significant long-term impact with its mRNA medicines, but declining sales amid plummeting demand for its COVID-19 vaccine, steep losses, and cash burn reflect uncertainty around its near-term prospects. As MRNA is set to release its fourth-quarter 2023 results this Thursday, let’s find…

StockNews.com

Moderna (MRNA) and Biogen (BIIB) - Are There Upsides Left in These Biotech Stocks?

Despite macroeconomic challenges, the biotech industry thrives on innovation, demand, adaptability, and technological advancements, demonstrating resilience. So, let’s analyze the upside potential of popular biotech stocks Biogen (BIIB) and Moderna (MRNA).

1 2 3 4 5

People

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.